{"title":"FDA approves first new class of treatment for schizophrenia in 30 years","authors":"Valerie A. Canady","doi":"10.1002/mhw.34198","DOIUrl":null,"url":null,"abstract":"<p>The U.S. Food and Drug Administration (FDA) on Sept. 26 approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for treating adult patients with schizophrenia. The move represents the first new class of treatment for this population in three decades.</p>","PeriodicalId":100916,"journal":{"name":"Mental Health Weekly","volume":"34 38","pages":"1-3"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mental Health Weekly","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mhw.34198","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The U.S. Food and Drug Administration (FDA) on Sept. 26 approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for treating adult patients with schizophrenia. The move represents the first new class of treatment for this population in three decades.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
